HOME >> BIOLOGY >> NEWS
PATH Malaria Vaccine Initiative announces partnership to develop novel malaria vaccine

Bethesda, MD, USA (December 14, 2006) In a move that promises to expand the types of malaria vaccine candidates in clinical development, the PATH Malaria Vaccine Initiative (MVI) today announced a new partnership with Sanaria Inc., a Maryland company, to accelerate development of a unique malaria vaccine candidate.

Supported by a $29.3 million grant to PATH from the Bill & Melinda Gates Foundation, this strategic partnership will focus on the development and manufacture of Sanaria's malaria vaccine candidateone that uses a novel, whole-parasite approach to preventing infection from the most deadly malaria parasite, Plasmodium falciparum. MVI and Sanaria will move quickly to conduct an initial safety and test-of-concept trial of the Sanaria candidate among volunteers in the United States.

"Close to one million children die of malaria each year," said Dr. Melinda Moree, Director of MVI. "With this support, we can examine another promising malaria vaccine technology and bring the field closer to delivering a safe, effective, and affordable pediatric malaria vaccine to at-risk communities in Africa."

Of the more than one million people who die of malaria every year, most of them are African children under five years old. Hundreds of millions more people suffer the effects of the mosquito-borne, parasitic disease each year. Scientists have been working for years to develop a preventive malaria vaccine and have recently demonstrated that such a vaccine is possible.

While the approach of much malaria vaccine research and development has centered on using one or more components of the malaria parasite that the human immune system can recognize, Sanaria is focused on using an attenuated, or weakened, form of the whole parasite. The idea is that when this attenuated parasite is given to individuals, they will become immune to malaria but will not get sick. This is the first vaccine candidate of its kind in the MVI portfolio.<
'"/>


14-Dec-2006


Page: 1 2

Related biology news :

1. Malaria -- Effective insecticide-repellent synergy against mosquito vectors
2. Malaria-resistant mosquitoes battle disease with molecular warhead
3. Malaria and Epstein-Barr virus linked to pediatric cancer in Africa
4. Malaria in pregnancy: What can the social sciences contribute?
5. Malaria: The right vaccine in the right place?
6. 20 Years of Malaria Research: Outcomes and Perspectives
7. Malaria poses additional risks for first-time mothers
8. Malaria drug may treat metabolic syndromes many symptoms
9. Malaria: Efficacy of monotherapies in Cameroon
10. Malaria, potato famine pathogen share surprising trait
11. Malaria parasite impairs key immune system cells

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/30/2020)... ... May 29, 2020 , ... ... transformation for enterprises globally, has collaborated with EchoNous Inc. to develop the cloud-based ... can measure systolic heart function, which has been clinically tested versus expert measurements, ...
(Date:5/28/2020)... , ... May 28, 2020 , ... ... that interim results from their 1801 Phase 1/2 study (NCT03678883, EudraCT #: 2018-003739-32) ... Meeting which will take place virtually on May 29th, 2020. Dr. Benedito Carneiro, ...
(Date:5/21/2020)... ... May 19, 2020 , ... ... provider of operations management solutions, today introduced BioMed to their award-winning computerized ... platform for connecting the people and systems around biomedical engineering to better ...
Breaking Biology News(10 mins):
(Date:5/21/2020)... ... May 19, 2020 , ... Experienced periodontist in Eden Prairie, ... implants and bone grafting through PIEZOSURGERY® technology. PIEZOSURGERY uses ultrasonic vibrations to ... to prepare a patient for dental implants, especially when the implants need to be ...
(Date:5/15/2020)... ... May 14, 2020 , ... Children with defective ... surgeries before becoming adults. The reason: there are no heart valve prosthetics ... need, the Department of Defense has awarded Draper, Boston Children’s Hospital and Seattle ...
(Date:5/14/2020)... ... May 12, 2020 , ... ... research, is bringing together thousands of industry leaders, clinicians, research scientists, medical professionals ... plenary speakers, Carl June, MD, Director of the Center for Cellular Immunotherapies at ...
(Date:5/5/2020)... ... May 04, 2020 , ... Red Nucleus, ... sciences industry, today announced that Informa Training Partners, a life sciences training company ... Red Nucleus Boston, effective immediately. , “The name change solidifies a stronger presence ...
Breaking Biology Technology:
Cached News: